Dr. Miia H Lim, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 76 State Street, 26th Floor, Boston, MA 02109 Phone: 888-982-7956 |
Kerry A Mcbrien, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 401 Park Dr, Boston, MA 02215 Phone: 617-246-6211 |
Dr. Jennifer L Trieu, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 850 Harrison Ave, Yacc 4, Boston, MA 02118 Phone: 617-414-2080 Fax: 617-414-2090 |
Dr. Julia Randall, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Boston Medical Ctr Pl, Bmc - Department Of Family Medicine Dowling 5, Boston, MA 02118 Phone: 617-638-6800 |
Dr. Juliana I Castedo, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4199 Washington St, Boston, MA 02131 Phone: 617-323-4440 Fax: 617-323-7870 |
Heli Naik, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 930 Commonwealth Ave, Boston, MA 02215 Phone: 617-414-6800 Fax: 617-414-6817 |
News Archive
Levels of biomarkers in the blood of pregnant women can be used to predict which women are at risk of pre-eclampsia, finds a study published today (22 July) in BJOG: An International Journal of Obstetrics and Gynaecology (BJOG). ADMA and Hcy, both known to be raised in women with pre-eclampsia, are present in the blood in higher than normal concentrations a month before the onset of the condition.
CRISPR/Cas9, a powerful genome editing tool, is showing promise for efficient correction of disease-causing mutations.
A report published in the journal Optometry & Vision Science demonstrated that patients who replaced their silicone hydrogel contact lenses according to the manufacturer recommended replacement frequency experienced better comfort and vision at the end of the day than non-compliant patients. The analysis was part of a larger study sponsored by CIBA VISION, which was developed to investigate contact lens replacement schedule compliance.
Mouse models have advanced our understanding of immune function and disease in many ways but they have failed to account for the natural diversity in human immune responses.
An advisory panel for the US Food and Drugs Administration voted 9-6 that the FDA should not yet approve dapagliflozin, a new type of diabetes drug that makes the body dump sugar and lose weight. Signals of possible liver damage and of breast and bladder cancer worried the experts.
› Verified 4 days ago